Insider Trades
News
businesswire.comVelocity Appoints Dean Thevaos as Chief Technology Officerbusinesswire.comJun 2
seekingalpha.comVelocity Financial, Inc. (VEL) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7
businesswire.comVelocity Financial, Inc. Reports First Quarter 2026 Resultsbusinesswire.comMay 6
globenewswire.comOSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patientsglobenewswire.comApr 27
businesswire.comVelocity Financial, Inc. Announces Date of First Quarter 2026 Financial Results Webcast and Conference Callbusinesswire.comApr 22